Symphogen, a Denmark-based developer of antibody therapeutics to treat cancer and disease, has added €41m ($54m) to its previous round. Novo, a $20bn quasi-corporate venturing investment company wholly owned by the Novo Nordisk Foundation, and local pension fund PKA each invested €20m, with Danica Pension co-investing. Henrik Gürtler, chief executive of Novo, said: “It is…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
